EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects

Michael T Patterson, Shanzay M Khan, Natalia S Nunes iD, Rochelle E Fletcher, Jing Bian iD, Ashley D Hadjis iD, Michael A Eckhaus, Suresh K Mendu iD, Alessandra de Paula Pohl, David J Venzon, Hyoyoung Choo-Wosoba, Kazusa Ishii und 4 weitere

Blood · 09.02.2023 · 141 (6) · 659-672

DOI: 10.1182/blood.2022016660 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 09.02.2023. Verfasst von Michael T Patterson und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Leukemia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CCR NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapse limits the therapeutic efficacy both of chimeric antigen receptor (CAR) T cells and allogeneic hematopoietic cell transplantation (allo-HCT). Patients may undergo these therapies sequentially to prevent or treat relapsed malignancy. However, direct integration of the 2 therapies has been avoided over concerns for potential induction of graft-versus-host disease (GVHD) by allogeneic CAR T cells. We have shown in murine T-cell-replete MHC-haploidentical allo-HCT that suppressive mechanisms induced immediately after posttransplant cyclophosphamide (PTCy), given on days +3/+4, prevent GVHD induction by alloreactive T cells infused as early as day +5. Therefore, we hypothesized that allogeneic CAR T cells given in a similarly integrated manner in our murine MHC-haploidentical allo-HCT model may safely exert antitumor effects. Indeed, allogeneic anti-CD19 CAR T cells given early after (day +5) PTCy or even prior to (day 0) PTCy cleared leukemia without exacerbating the cytokine release syndrome occurring from the MHC-haploidentical allo-HCT or interfering with PTCy-mediated GVHD prevention. Meanwhile, CAR T-cell treatment on day +9 or day +14 was safe but less effective, suggesting a limited therapeutic window. CAR T cells infused before PTCy were not eliminated, but surviving CAR T cells continued to proliferate highly and expand despite PTCy. In comparison with infusion on day +5, CAR T-cell infusion on day 0 demonstrated superior clinical efficacy associated with earlier CAR T-cell expansion, higher phenotypic CAR T-cell activation, less CD4+CD25+Foxp3+ CAR T-cell recovery, and transcriptional changes suggesting increased activation of CD4+ CAR T cells and more cytotoxic CD8+ CAR T cells. This study provides mechanistic insight into PTCy’s impact on graft-versus-tumor immunity and describes novel approaches to integrate CAR T cells and allo-HCT that may compensate for deficiencies of each individual approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationGraft vs Host DiseaseLeukemiaHumansMiceAnimalsCyclophosphamideCD4-Positive T-Lymphocytes

Substanzen

Cyclophosphamide

Autor:innen und Institutionen

  • Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Division of Veterinary Resources, Office of Research Services, National Institutes of Health, Bethesda, MD.
  • Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

ORCID-Profile: Natalia S Nunes, Jing Bian, Ashley D Hadjis, Suresh K Mendu, Terry J Fry

Förderung

  • CCR NIH HHS
  • NCI NIH HHS

Zitieren

APA

Patterson, M. T., Khan, S. M., Nunes, N. S., Fletcher, R. E., Bian, J., Hadjis, A. D., Eckhaus, M. A., Mendu, S. K., de Paula Pohl, A., Venzon, D. J., Choo-Wosoba, H., Ishii, K., Qin, H., Fry, T. J., Cam, M., & Kanakry, C. G. (2023). Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects. Blood, 141(6), 659-672. https://doi.org/10.1182/blood.2022016660

Vancouver

Patterson MT, Khan SM, Nunes NS, Fletcher RE, Bian J, Hadjis AD, et al. Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects. Blood. 2023;141(6):659-672. doi:10.1182/blood.2022016660

BibTeX
@article{Patterson2023,
  author = {Patterson, Michael T and Khan, Shanzay M and Nunes, Natalia S and Fletcher, Rochelle E and Bian, Jing and Hadjis, Ashley D and Eckhaus, Michael A and Mendu, Suresh K and de Paula Pohl, Alessandra and Venzon, David J and Choo-Wosoba, Hyoyoung and Ishii, Kazusa and Qin, Haiying and Fry, Terry J and Cam, Maggie and Kanakry, Christopher G},
  title = {Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects},
  journal = {Blood},
  year = {2023},
  volume = {141},
  number = {6},
  pages = {659--672},
  doi = {10.1182/blood.2022016660}
}
Kostenlos starten →